1. The Lancet Respiratory Medicine 2017 ; 5(5): 390-400. - Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. / Chupp,G.L., et al.

2. The Lancet Respiratory Medicine 2022 ; 10(1): 11-25. - Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. / Wechsler, M. E., et al.

3. The Journal of Allergy and Clinical Immunology: In Practice 2019 ; 7(2): 589-596.e583. - Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. / Weinstein, S. F., et al.


기사명/잡지명 :
저자명 :
ISSN :
Vol./No. :
페이지(시작-끝) :
PMID :